Phylogica

 

 

Drug discovery company Phylogica (ASX:PYC) is the first commercial spin-out from the Telethon Institute for Child Health Research. Phylogica's innovative Phylomer (R) technology targets and blocks disease protein interactions, constituting a drug discovery engine designed to produce cost-effective therapies with fewer side effects than existing treatments. Phylogica is applying its Phylomer (R) peptides to block common pathways in inflammation in conditions such as rheumatoid athritis, allergies, diabetes, stroke and burn injury.

 

>> Visit the Phylogica Limited website